CNS Pharmaceuticals, Inc. is a Houston-based biopharmaceutical company focusing on developing treatments for brain cancers and neurological conditions, particularly targeting drug candidates like Berubicin.

# Summary of CNS Pharmaceuticals, Inc.

**Company Overview**  
CNS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatments for brain cancers and neurological indications. Its primary activities involve research, development, and potential commercialization of innovative drugs targeting difficult-to-treat brain cancers.

**Key Details**  
- **Location:** Houston, Texas  
- **Principal Address:** 2100 West Loop South, Suite 900, Houston, TX 77027  
- **Filing Status:** Filed a Form 10-K/A for the fiscal year ending December 31, 2024 (Amended to include Part III information, last filed March 31, 2025).  
- **Market Capitalization:** Approximately $8.78 million (as of the last disclosure date) based on the last sale of voting equity held by non-affiliates.  
- **Number of Shares Outstanding:** 2,944,381 shares as of March 31, 2025.  
- **Employees:** Not explicitly stated.  
- **Revenue and Income:** Not provided in the document.  
- **Customers:** Not specified.  

**Business Focus**  
CNS Pharmaceuticals concentrates on developing novel therapies for brain cancers, with a particular focus on drug candidates such as Berubicin. The company is involved in intellectual property development, clinical trial activities, and securing regulatory approvals, including efforts toward submission of a New Drug Application (NDA).

**Corporate Governance & Management**  
- **Board of Directors:** Includes experts with backgrounds in law, biotechnology, finance, and scientific research.  
- **Executive Officers:** Includes a CEO, CFO, Chief Medical Officer, and Chief Science Officer, with experience in healthcare leadership, drug development, and clinical research.

**Financial Data (Selected)**  
- **Revenue, profit, and customer data:** Not disclosed in the provided document.  
- **Employees:** Not disclosed.  
- **Recent Financials:** The document primarily contains disclosures related to corporate governance, executive compensation, stock ownership, and legal arrangements, but does not specify financial results such as revenue, net income, or number of customers.

---

*Note:* This summary is based solely on the provided excerpt of the company's SEC filing. It contains detailed corporate information, governance, management, and stock-related disclosures but lacks specific financial figures, customer metrics, or employment numbers.

A clinical pharmaceutical company focused on developing the anti-cancer drug Berubicin for treating glioblastoma and CNS tumors, with significant ongoing R&D investment and a small operational team.

# Company Overview: Clinical Pharmaceutical Company

## Business Focus
The company, incorporated in July 2017 in Nevada, is a clinical pharmaceutical entity primarily concentrating on the development of anti-cancer drug candidates aimed at treating brain and central nervous system (CNS) tumors. The lead drug candidate being developed is **Berubicin**, which is perceived to have significant potential as a treatment for glioblastoma and other CNS malignancies. 

### Intellectual Property and Licenses
- **Berubicin** was discovered at The University of Texas M.D. Anderson Cancer Center (UTMDACC) by Dr. Waldemar Priebe, the company's founder.
- The company has obtained rights through various agreements:
  - **HPI License**: A worldwide exclusive license for the chemical compound Berubicin from Houston Pharmaceuticals, Inc. (HPI).
  - **Reata Agreement**: Acquired all intellectual property and development data related to Berubicin from Reata Pharmaceuticals, including past clinical trial data.
  - **WP1244 Agreement**: License rights from UTMDACC for WP1244 drug technology.

## Products and Clinical Trials
### Lead Product: Berubicin
- **Type**: Anthracycline chemotherapy drug.
- **Current Development Stage**: Conducting a Phase 2 randomized controlled trial (CNS-201) comparing Berubicin with Lomustine (CCNU) for patients with recurrent glioblastoma.
- **Trial Progress**: First patient dosed in Q3 2021; independent Data Safety Monitoring Board (DSMB) recommended to continue the study without modifications as of December 18, 2023.

### Research and Development
- **Investment in R&D**: The company plans to invest in research for additional cancer treatments and is interested in securing intellectual property rights for more compounds.
  
## Financials
- **Revenue**: The company has not generated revenue from product sales as of December 31, 2023.
- **Profitability**: The company has never been profitable, with an accumulated deficit of approximately **$69.57 million** since inception.
- **Capital Needs**: Estimated additional financing needs of approximately **$15 million to $17 million** to complete current clinical trials and fund ongoing operations. 

## Employees
- **Team Size**: As of April 1, 2024, the company has **three full-time employees**, along with two part-time employees who serve as chief medical and scientific officers.

## Customer Base
- **Customers**: The company focuses on developing therapeutics for glioblastoma, primarily targeting healthcare providers and institutions involved in oncology.

## Conclusion
This clinical pharmaceutical company is engaged in pivotal cancer drug development, primarily focused on Berubicin for glioblastoma treatment, and relies heavily on successful fundraising and regulatory processes to advance its products. With no current revenue streams and a small team, the company's operations are highly dependent on the successful advancement of its clinical trials and securing additional funding.

CNS Pharmaceuticals, Inc.

10-K / April 30, 2025

10-K / April 1, 2024

10-K / April 30, 2025

Summary of CNS Pharmaceuticals, Inc.